Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P23942

UPID:
PRPH2_HUMAN

ALTERNATIVE NAMES:
Retinal degeneration slow protein; Tetraspanin-22

ALTERNATIVE UPACC:
P23942; Q5TFH5; Q6DK65

BACKGROUND:
Peripherin-2, identified by its alternative names Retinal degeneration slow protein and Tetraspanin-22, is integral to retinal photoreceptor function. It supports the formation and maintenance of photoreceptor outer segment disks, crucial for capturing visual information. Additionally, it ensures the proper thickness of the retinal outer nuclear layer and organizes the photoreceptor inner segment, highlighting its comprehensive role in eye health.

THERAPEUTIC SIGNIFICANCE:
The association of Peripherin-2 with retinal dystrophies, including Retinitis pigmentosa 7 and various macular dystrophies, underscores its therapeutic potential. Targeting Peripherin-2 in drug discovery efforts could lead to innovative treatments for these vision-impairing diseases. Understanding the role of Peripherin-2 could open doors to potential therapeutic strategies, marking a significant step forward in combating retinal degenerative diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.